Relationship Between Hemagglutination Index And Clinical Pathology Characteristic In310Patients With Malignant Tumor

BackgroundMany patients with malignant tumor have different systemic complications and the complications are the important factors influencing the patients with tumor treatment and prognosis. In recent years, coagulation disorders as a common complication of patients with malignant tumor has been paid much attention, but now, the specific mechanism of malignant tumor concurrent with coagulation disorders is unclear yet. This article explored the possible mechanisms of malignant tumor combined coagulation disorders and blood coagulation dysfunction relations with tumor stage and metastasis by analysis of blood coagulation in310patients with malignant tumor.Patients and MethodsThe index (PT, APTT, TT, Fib, D-dimer, PLT) of310hospitalized patients with malignant tumor and243patients as control in Provincial Hospital Affiliated to Shandong University from January1,2010to October31,2012were collected. Statistical data were analysed by software SPSS13.0for Windows. Large sample U test was used to compare the index. P<0.05was considered as statistically significant, while P<0.01was considered as dramatically statistically significant.ResultsAmong the310patients with malignant tumor, there are126men cases and117women ones; age ranges from16to89years old. and55years old for average; different types of tumor are as follows:lung cancer100cases, colon-rectal cancer36cases, gastric cancer31cases, esophageal cancer30cases, breast cancer29cases, liver and biliary cancer16cases, nasopharyngeal cancer9case, ovarian cancer8cases, lymphoma8cases, nephritic cancer7cases, pancreatic cancer6cases, cervical cancer4cases, brain cancer4cases, the cancer of unknown primary site4cases, endometrial cancer3case, prostate cancer3cases, bladder cancer2cases, other cancer10case.Among the243patients as control, there are126men cases and117women ones; age ranges from16to89years old, and55years old for average. They are all non-tumor patients who receive residential treatment in ophthalmology department of Provincial Hospital Affiliated to Shandong University from June1,2012to December31,2010.The two groups can match for the general demographic characteristics.2.Comparison of abnormal cases and rate between malignant tumor and control groupThere are168abnormal cases in malignant tumor group, abnormal rate is54.2%, while there are48abnormal cases in control group, abnormal rate is19.8%. The difference is statistically significant (P<0.01).3.Comparison of hemagglutination index between malignant tumor and control groupPT, APTT, Fib and D-dimer are significantly higher in tumor patients(P<0.01); While TT, PLT does not change markedly (P>0.05).4.Comparison of hemagglutination index between initial and comprehensive treatment groupPT and D-dimer are significantly higher in comprehensive treatment patients(P<0.01); While TT, Fib, PLT does not change markedly (P>0.05).5.Comparison of hemagglutination index among different types of tumorFib varies largely in different types of tumor. There are statistical differences of Fib in lung cancer, esophageal cancer and colon-rectal cancer patients(P<0.01); PT, APTT and D-dimer are higher in all the types (P<0.05); TT is lower in most types (P<0.05). 6.Comparison of hemagglutination index among tumor of different stage PT and APTT in stage Ⅳ cancer patients are significantly higher comparing to stage Ⅰ-Ⅲ cancer patients.ConclusionCoagulation disorder definitely exists in the patients with malignant tumor. The rising of PT, APTT, D-dimer in tumor patients is a risk factor that lead to thrombotic disease, which should be properly monitored in order to decrease the happen of correlated complications. The disorder may has a relationship with tumor itself, treatment process and tumor types. But the specific interaction among them has not been decided yet. That is what we should research next.